

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-18. (canceled)

19. (new) A method for confirming a clinical diagnosis of a sepsis in a patient suspected of having sepsis, the method comprising:

- a) determining the concentration of LIM and SH3 Domain Protein-1 (LASP-1) and at least one further biomarker for sepsis in a blood or serum sample from said patient; and
- b) comparing said concentrations to the corresponding concentration in a control sample,

wherein an elevated concentration of a LASP-1 protein and at least one further biomarker for sepsis with reference to said control sample is indicative of sepsis.

20. (new) The method of claim 19, wherein the concentration of LASP-1 protein is determined by an immunodiagnostic assay of the sandwich type.

21. (new) The method of claim 20, wherein the immunoreactivity of the LASP-1 protein from amino acid positions 121-187 of SEQ ID NO: 1 is determined.

22. (new) The method of claim 20, wherein the immunodiagnostic assay employs antibody reagents produced from a protein having SEQ ID NO:13 or from a protein having SEQ ID NO: 17.

23. (new) The method of claim 21, wherein the LASP-1 protein is in a posttranslational soluble form.

24. (new) The method of claim 23, wherein the protein is glycosylated.

25. (new) The method of claim 23, wherein the protein is phosphorylated.
26. (new) The method of claim 19, wherein said at least one further biomarker is procalcitonin.
27. (new) The method of claim 19, wherein the determining step is performed simultaneously.

* * * * *